The cardiovascular system medicine sales in Finland are forecasted to decline from $141.6 million in 2024 to $133.6 million in 2028. The year-on-year variation indicates a steady decline: -1.91% from 2024 to 2025, -1.58% from 2025 to 2026, -1.32% from 2026 to 2027, and -0.97% from 2027 to 2028. The compound annual growth rate (CAGR) from 2023 to 2028 is expected to be -1.38%, reflecting an overall decrease in market size.
Future trends to watch for:
• Technological advancements in cardiovascular treatment methods.
• Changes in regulatory policies impacting drug pricing and reimbursements.
• Demographic shifts, such as an aging population, which might influence demand for cardiovascular medications.
• Emerging competition from generic drugs and biosimilars.
